Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT02060253
Title Ganetespib, Paclitaxel and Trastuzumab for Advanced or Metastatic Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Breast Cancer
Recruitment Completed
Gender both
Phase Phase I
Variant Requirements No
Sponsors New York University School of Medicine

Her2-receptor positive breast cancer


Ganetespib + Paclitaxel + Trastuzumab

Age Groups: adult
Covered Countries USA

No variant requirements are available.